[1] 陈万青, 李贺, 孙可欣, 等.  2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志, 2018, 40(1): 5-13.   doi: 10.3760/cma.j.issn.0253-3766.2018.01.002
Chen WQ, Li H, Sun KX, et al.  Report of Cancer Incidence and Mortality in China, 2014[J]. Chin J Oncol, 2018, 40(1): 5-13.   doi: 10.3760/cma.j.issn.0253-3766.2018.01.002
[2] Jones DR, Parker LA Jr, Detterbeck FC, et al.  Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy[J]. Cancer, 1999, 85(5): 1026-1032.   doi: 10.1002/(SICI)1097-0142(19990301)85:5<1026::AID-CNCR3>3.0.CO;2-N
[3] Laterza E, De Manzoni G, Guglielmi A, et al.  Endoscopic Ultrasonography in the Staging of Esophageal Carcinoma After Preoperative Radiotherapy and Chemotherapy[J]. Ann Thorac Surg, 1999, 67(5): 1466-1469.   doi: 10.1016/S0003-4975(99)00267-2
[4] Westerterp M, Van Westreenen HL, Reitsma JB, et al.  Esophageal Cancer: CT, Endoscopic US, and FDG PET for Assessment of Response to Neoadjuvant Therapy—Systematic Review[J]. Radiology, 2005, 236(3): 841-851.   doi: 10.1148/radiol.2363041042
[5] Kroep JR, Van Groeningen CJ, Cuesta MA, et al.  Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods[J]. Mol Imaging Biol, 2003, 5(5): 337-346.   doi: 10.1016/j.mibio.2003.09.007
[6] Kukar M, Alnaji RM, Jabi F, et al.  Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma[J]. JAMA Surg, 2015, 150(6): 555-562.   doi: 10.1001/jamasurg.2014.3867
[7] 李夷民, 林勤, 王丽琛, 等.  序贯18F-FDG PET/CT显像在非手术治疗食管癌同步放化疗疗效预测中的价值[J]. 中华核医学与分子影像杂志, 2013, 33(6): 405-411.   doi: 10.3760/cma.j.issn.2095-2848.2013.06.002
Li YM, Lin Q, Wang LC, et al.  Predictive value of sequential 18F-FDG PET/CT scan in concurrent chemoradiotherapy of non-surgical esophageal carcinoma[J]. Chin J Nucl Med Mol Imaging, 2013, 33(6): 405-411.   doi: 10.3760/cma.j.issn.2095-2848.2013.06.002
[8] Xi M, Liao ZX, Hofstetter WL, et al.  18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma[J]. J Nucl Med, 2017, 58(11): 1756-1763.   doi: 10.2967/jnumed.117.192591
[9] Van Rossum PSN, Fried DV, Zhang LF, et al.  The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma[J]. Eur J Nucl Med Mol Imaging, 2017, 44(1): 71-80.   doi: 10.1007/s00259-016-3478-2
[10] Chhabra A, Ong LT, Kuk D, et al.  Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma[J]. Br J Cancer, 2015, 113(12): 1658-1665.   doi: 10.1038/bjc.2015.416
[11] Arnett ALH, Merrell KW, Macintosh EM, et al.  Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation[J]. J Thorac Oncol, 2017, 12(1): 121-128.   doi: 10.1016/j.jtho.2016.08.136
[12] Elliott JA, O'Farrell NJ, King S, et al.  Value of CT–PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma[J]. Br J Surg, 2014, 101(13): 1702-1711.   doi: 10.1002/bjs.9670
[13] Piessen G, Petyt G, Duhamel A, et al.  Ineffectiveness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Tumor Response After Completion of Neoadjuvant Chemoradiation in Esophageal Cancer[J]. Ann Surg, 2013, 258(1): 66-76.   doi: 10.1097/SLA.0b013e31828676c4
[14] Wieder HA, Brücher BLDM, Zimmermann F, et al.  Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment[J]. J Clin Oncol, 2004, 22(5): 900-908.   doi: 10.1200/JCO.2004.07.122
[15] Kwee RM.  Prediction of Tumor Response to Neoadjuvant Therapy in Patients with Esophageal Cancer with Use of 18F FDG PET: A Systematic Review[J]. Radiology, 2010, 254(3): 707-717.   doi: 10.1148/radiol.09091324
[16] Jayachandran P, Pai RK, Quon A, et al.  Postchemoradiotherapy Positron Emission Tomography Predicts Pathologic Response and Survival in Patients With Esophageal Cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 84(2): 471-477.   doi: 10.1016/j.ijrobp.2011.12.029
[17] Elimova E, Wang XM, Etchebehere E, et al.  18F-FDG PET/CT as Predictive of Response after Chemoradiation in Esophageal Cancer Patients[J]. Eur J Cancer, 2015, 51(17): 2545-2552.   doi: 10.1016/j.ejca.2015.07.044
[18] Young H, Baum R, Cremerius U, et al.  Measurement of clinical and subclinical tumour response using[18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations[J]. Eur J Cancer, 1999, 35(13): 1773-1782.   doi: 10.1016/S0959-8049(99)00229-4
[19] Wahl RL, Jacene H, Kasamon Y, et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors[J]. J Nucl Med, 2009, 50(S1): S122-150.   doi: 10.2967/jnumed.108.057307
[20] Yanagawa M, Tatsumi M, Miyata H, et al.  Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors[J]. J Nucl Med, 2012, 53(6): 872-880.   doi: 10.2967/jnumed.111.098699
[21] Been LB, Suurmeijer AJH, Cobben DCP, et al.  [18F]FLT-PET in oncology: current status and opportunities[J]. Eur J Nucl Med Mol Imaging, 2004, 31(12): 1659-1672.   doi: 10.1007/s00259-004-1687-6
[22] Yue JB, Chen LS, Cabrera AR, et al.  Measuring Tumor Cell Proliferation with 18F-FLT PET During Radiotherapy of Esophageal Squamous Cell Carcinoma: A Pilot Clinical Study[J]. J Nucl Med, 2010, 51(4): 528-534.   doi: 10.2967/jnumed.109.072124
[23] Chen HJ, Li YM, Wu H, et al.  3’-Deoxy-3’-[18F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: Comparison with[18F]-FDG PET/CT[J]. Strahlenther Onkol, 2015, 191(2): 141-152.   doi: 10.1007/s00066-014-0744-8
[24] Nordsmark M, Bentzen SM, Rudat V, et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study[J]. Radiother Oncol, 2005, 77(1): 18-24.   doi: 10.1016/j.radonc.2005.06.038
[25] Rajendran JG, Wilson DC, Conrad EU, et al.  [18F]FMISO and[18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression[J]. Eur J Nucl Med Mol Imaging, 2003, 30(5): 695-704.   doi: 10.1007/s00259-002-1096-7
[26] Rasey JS, Koh WJ, Evans ML, et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of[18F]fluoromisonidazole: A pretherapy study of 37 patients[J]. Int J Radiat Oncol Biol Phys, 1996, 36(2): 417-428.   doi: 10.1016/S0360-016(96)00325-2
[27] Rajendran JG, Schwartz DL, O'Sullivan J, et al.  Tumor Hypoxia Imaging with[F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer[J]. Clin Cancer Res, 2006, 12(18): 5435-5441.   doi: 10.1158/1078-0432.CCR-05-1773
[28] Okamoto S, Shiga T, Yasuda K, et al.  High Reproducibility of Tumor Hypoxia Evaluated by 18F-Fluoromisonidazole PET for Head and Neck Cancer[J]. J Nucl Med, 2013, 54(2): 201-207.   doi: 10.2967/jnumed.112.109330
[29] Grkovski M, Schwartz J, Gönen M, et al.  Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times[J]. J Nucl Med, 2016, 57(3): 334-341.   doi: 10.2967/jnumed.115.160168
[30] Tachibana I, Nishimura Y, Shibata T, et al.  A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy[J]. J Radiat Res, 2013, 54(6): 1078-1084.   doi: 10.1093/jrr/rrt033
[31] Okamoto S, Shiga T, Yasuda K, et al.  The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy[J]. Eur J Nucl Med Mol Imaging, 2016, 43(12): 2147-2154.   doi: 10.1007/s00259-016-3431-4
[32] Grönroos T, Eskola O, Lehtiö K, et al.  Pharmacokinetics of[18F]FETNIM: A Potential Hypoxia Marker for PET[J]. J Nucl Med, 2001, 42(9): 1397-1404.
[33] Lehtiö K, Oikonen V, Nyman S, et al.  Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio[J]. Eur J Nucl Med Mol Imaging, 2003, 30(1): 101-108.   doi: 10.1007/s00259-002-1016-x
[34] Grönroos T, Bentzen L, Marjamäki P, et al.  Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and[18F]FMISO in an experimental mammary carcinoma[J]. Eur J Nucl Med Mol Imaging, 2004, 31(4): 513-520.   doi: 10.1007/s00259-003-1404-x
[35] Yang DJ, Wallace S, Cherif A, et al.  Development of F-18-labeled Fluoroerythronitroimidazole as a PET Agent for Imaging Tumor Hypoxia[J]. Radiology, 1995, 194(3): 795-800.   doi: 10.1148/radiology.194.3.7862981
[36] Yue J, Yang Y, Cabrera AR, et al.  Measuring tumor hypoxia with 18F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study[J]. Dis Esophagus, 2012, 25(1): 54-61.   doi: 10.1111/j.1442-2050.2011.01209.x
[37] Höglund J, Shirvan A, Antoni G, et al.  18F-ML-10, a PET Tracer for Apoptosis: First Human Study[J]. J Nucl Med, 2011, 52(5): 720-725.   doi: 10.2967/jnumed.110.081786
[38]

胡四龙. 18F-ML-10 PET/CT评价胰腺癌放化疗后细胞凋亡的实验研究[D]. 上海: 复旦大学, 2013.

Hu SL. Experimental study on the evaluation of apoptosis in pancreatic cancer after chemotherapy and radiotherapy with 18F-ML-10 PET/CT[D]. Shanghai: Fudan University, 2013.
[39] Reshef A, Shirvan A, Waterhouse RN, et al.  Molecular Imaging of Neurovascular Cell Death in Experimental Cerebral Stroke by PET[J]. J Nucl Med, 2008, 49(9): 1520-1528.   doi: 10.2967/jnumed.107.043919
[40] Allen AM, Ben-Ami M, Reshef A, et al.  Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9): 1400-1408.   doi: 10.1007/s00259-012-2150-8
[41] Sun L, Zhou KD, Wang WJ, et al.  [18F]ML-10 Imaging for Assessment of Apoptosis Response of Intracranial Tumor Early after Radiosurgery by PET/CT[J]. Contrast Media Mol Imaging, 2018, 2018: 9365174-.   doi: 10.1155/2018/9365174